Analytical Data
-
Gene name
LILRA4/ILT-7/CD85g
-
简介
The LILRA4/ILT-7/CD85g protein is a coreceptor that critically limits the innate immune response during viral infection through FCER1G signaling. It negatively regulates TLR7 and TLR9 signaling and reduces IFNA1, IFNA2, IFNA4, IFNB1, and TNF production in dendritic cells exposed to influenza virus or CpG dinucleotides. LILRA4/ILT-7/CD85g Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived LILRA4/ILT-7/CD85g protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
Alternative Names
CD85g; ILT7; ILT-7; ILT7MGC129598; LILRA4; MGC129597
-
Species
Cynomolgus
-
Source
HEK293
-
Tag
C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
XP_005590346
-
Expression Region
E24-N446
-
Protein Length
Partial
-
Molecular Weight
60-70 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LILRA4, also known as ILT-7 or CD85g, is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which plays a crucial role in immune regulation. The protein is predominantly expressed on plasmacytoid dendritic cells (pDCs) and is involved in mediating the immune response to viral infections and autoimmune diseases. Research on LILRA4 has gained traction due to its alternative splicing variants that can function as either activating or inhibitory receptors, thus contributing to a nuanced understanding of immune signaling pathways. LILRA4 interacts with various ligands, including MHC class I molecules, which modulates the activation of immune cells. The study of LILRA4 as a recombinant protein holds significant potential for therapeutic applications, particularly in the context of enhancing antiviral immunity or dampening excessive immune responses in autoimmune disorders. Understanding the structure and function of this receptor can also facilitate the development of novel immunotherapeutic strategies aimed at targeting pDCs and their role in immunopathology. Given its pivotal function in balancing immune responses, LILRA4 is a promising target for research focused on designing targeted therapies that improve outcomes in infectious and autoimmune diseases.
